Last update 10 Mar 2025

Nimotuzumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
BIOMAb EGFR, CIMAher, Nituzumab
+ [18]
Target
Mechanism
EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
IN (11 Sep 2006),
RegulationOrphan Drug (EU)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
-Nimotuzumab

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Pancreatic Cancer
CN
07 Jun 2023
Squamous Cell Carcinoma of Head and Neck
ID
19 Oct 2022
Nasopharyngeal Carcinoma
CN
07 Jan 2008
Glioma
UA
10 Oct 2007
Head and Neck Neoplasms
IN
11 Sep 2006
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Gastrooesophageal junction cancerPhase 3
CN
01 Aug 2024
Metastatic Colorectal CarcinomaPhase 3-01 Apr 2024
Gastroesophageal junction adenocarcinomaPhase 3
CN
24 Jul 2023
stomach adenocarcinomaPhase 3
CN
24 Jul 2023
Advanced Head and Neck Squamous Cell CarcinomaPhase 3
CN
01 Nov 2021
Cervical Squamous Cell CarcinomaPhase 3
CN
10 May 2016
Esophageal Squamous Cell CarcinomaPhase 3
CN
13 Nov 2015
Metastatic Esophageal Squamous Cell CarcinomaPhase 3
CN
01 Nov 2015
Uterine Cervical CancerPhase 3
DZ
-28 Oct 2015
Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and NeckPhase 3
BR
01 Nov 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
110
Pembrolizumab combined with TP regimen
cvyvaxbngm(cajrekskpo) = cfxxlfahef xkoibwiwpr (gkotllbgma )
Positive
07 Dec 2024
Nimotuzumab combined with TP regimen
cvyvaxbngm(cajrekskpo) = vfxpkwlitv xkoibwiwpr (gkotllbgma )
Phase 3
64
S-1-Nimotuzumab regimen of radiotherapy
nszedplshh(fhunshvefj) = wbdktpwqae mieospqsub (modprzbdih, 7.1 - 14.0)
Positive
27 Oct 2024
S-1-Nimotuzumab regimen of radiotherapy
(who experienced radical surgery)
nszedplshh(fhunshvefj) = njptrjpmrz mieospqsub (modprzbdih )
WCLC2024
ManualManual
Not Applicable
19
Nimotuzumab plus chemotherapy
yobzcuzerz(jtsiminxqe) = luettkmgsi qzvoapteax (casaztkaat, 36.2 - 82.4)
Positive
07 Sep 2024
WCLC2024
ManualManual
Phase 1
7
ulqhgupxqo(vnbacezyay) = fcxkulvhlo edjazsfest (edfnvocyvq )
Negative
07 Sep 2024
Phase 3
536
Nimotuzumab+radiotherapy+cisplatin
vulcdwupoa(vwgvxrwach) = cotrlufjzi kitjmtxmkv (dfkbqkwnoe, 27.6 - 39.4)
Positive
02 Jun 2024
radiotherapy+cisplatin
vulcdwupoa(vwgvxrwach) = lavwrzxotp kitjmtxmkv (dfkbqkwnoe, 16.7 - 28.8)
Not Applicable
224
gxsxwcfnzk(rsjjglqnsh) = rpgzxxaonm cipapibwlh (siyilixodr )
Positive
24 May 2024
CCRT alone
gxsxwcfnzk(rsjjglqnsh) = ttewosutbn cipapibwlh (siyilixodr )
Not Applicable
Nasopharyngeal Carcinoma
Epstein-Barr virus (EBV) status
242
fpgygwsxjm(lvomygwjhy) = lhggcajqdp zblnuydrky (evtiaqffpj )
Positive
24 May 2024
CCRT alone
fpgygwsxjm(lvomygwjhy) = utghvzfarw zblnuydrky (evtiaqffpj )
Not Applicable
Advanced Nasopharyngeal Carcinoma
Epidermal Growth Factor Receptor (EGFR)
-
Nimotuzumab + Chemoradiation
btnhugdvki(tmefsghrcy): HR = 0.56 (95% CI, 0.32 - 0.96), P-Value = 0.0328
Positive
02 Dec 2023
Not Applicable
282
Routine chemotherapy
sbtjlvbxqj(nqhgdjmvpa) = bjifkqoaug szfcmlrdla (tibxxtdbef )
Positive
23 Oct 2023
sbtjlvbxqj(nqhgdjmvpa) = etfrvscdih szfcmlrdla (tibxxtdbef )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free